KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Biomarin Pharmaceutical (BMRN) over the last 17 years, with Q3 2025 value amounting to $28.4 million.

  • Biomarin Pharmaceutical's Capital Expenditures rose 5407.57% to $28.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $81.8 million, marking a year-over-year decrease of 1367.46%. This contributed to the annual value of $85.4 million for FY2024, which is 1165.26% down from last year.
  • Per Biomarin Pharmaceutical's latest filing, its Capital Expenditures stood at $28.4 million for Q3 2025, which was up 5407.57% from $17.1 million recorded in Q2 2025.
  • Over the past 5 years, Biomarin Pharmaceutical's Capital Expenditures peaked at $35.7 million during Q4 2022, and registered a low of $16.8 million during Q1 2025.
  • Moreover, its 5-year median value for Capital Expenditures was $24.5 million (2023), whereas its average is $24.3 million.
  • As far as peak fluctuations go, Biomarin Pharmaceutical's Capital Expenditures crashed by 3710.36% in 2021, and later soared by 5640.01% in 2022.
  • Quarter analysis of 5 years shows Biomarin Pharmaceutical's Capital Expenditures stood at $28.7 million in 2021, then grew by 24.18% to $35.7 million in 2022, then decreased by 18.97% to $28.9 million in 2023, then crashed by 32.46% to $19.5 million in 2024, then surged by 45.66% to $28.4 million in 2025.
  • Its Capital Expenditures stands at $28.4 million for Q3 2025, versus $17.1 million for Q2 2025 and $16.8 million for Q1 2025.